Jarryd

Jarryd asked about the timing for moving shingles and RSV programs into the clinic, questioning if it could be a 2028 situation, and if partnerships for these programs could influence expediency and selection for clinical advancement.

Answer

CEO John Jacobs explained that R&D investments support Matrix technology expansion, new adjuvant creation, and early-stage assets to drive partnering opportunities and generate proof points. He reiterated the goal of being in the clinic with one or more assets as early as 2027. Chief Strategy Officer Elaine O'Hara added that programs were selected based on market opportunity and unmet medical need, and discussions with partners will begin as relevant data becomes available. Head of R&D Ruxandra Draghia highlighted that the C. diff program, in particular, is approaching the challenge differently from past failed attempts, using a multivalent antigen approach and Matrix-M.